The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy

References

• Limb GA, Alam A, Earley O, et al. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 1994;13:791–798.
   PubMed Web of Science ®Google Scholar
• Moysidis SN, Thanos A, Vavvas DG. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators Inflamm 2012;2012:815937.
   PubMed Web of Science ®Google Scholar
• Charteris DG, Sethi CS, Lewis GP, et al. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye 2002;16:369–374.
   PubMed Web of Science ®Google Scholar
• Frenzel E, Neely KA, Walsh AW, et al. A new model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998;39:2157–2164.
   PubMed Web of Science ®Google Scholar
• Ozerdem U, Mach-Hofacre B, Cheng L, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res 2000; 20:447–453.
   Google Scholar
• Liang C, Peyman GA, Conway MD, et al. Retinal toxicity of intravitreous octreotide in the rabbit. Can J Ophthalmol 1997;32:229–232.
   PubMed Web of Science ®Google Scholar
• Robertson JE, Westra I, Woltering EA, et al. Intravitreal injection of octreotide acetate. J Ocul Pharmacol Ther 1997;13:171–177.
   PubMed Web of Science ®Google Scholar
• Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008;49:1151–1156.
   PubMed Web of Science ®Google Scholar
• Giansanti F, Ramazzotti M, Giuntoli , et al. Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques. Invest Ophthalmol Vis Sci 2009;50:5328–5335.
   PubMed Web of Science ®Google Scholar
• Valeria Canto SM, Gallo JE, Dodds RA, et al. A mouse model of PVR induced by dispase. Exp Eye Res 2002;77:491–504.
   Web of Science ®Google Scholar
• Girard P, Mimoun G, Kurpouzas I, et al. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 1994;14:417–424.
   PubMed Web of Science ®Google Scholar
• Speicher MA, Fu AD, Martin JP, von Fricken MA. Primary vitrectomy alone for repair of retinal detachments following cataract surgery. Retina 2000;20:459–464.
   PubMed Web of Science ®Google Scholar
• Duquesne N, Bonnet M, Adeleine P. Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefe’s Arch Clin Exp Ophthalmol 1996;234:677–682.
   PubMed Web of Science ®Google Scholar
• Greven CM, Sanders RJ, Brown GC, et al. Pseudophakic retinal detachments. Anatomic and visual results. Ophthalmology 1992;99:257–262.
   PubMed Web of Science ®Google Scholar
• Gartry DS, Chignell AH, Franks WA, et al. Pars plana vitrectomy for the treatment of rhegmatogenous retinal detachment uncomplicated by advanced proliferative vitreoretinopathy. Br J Ophthalmol 1993;77:199–203.
   PubMed Web of Science ®Google Scholar
• Bonnet M, Fleury J, Guenoun S, et al. Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefe’s Arch Clin Exp Ophthalmol 1996;234:739–743.
   PubMed Web of Science ®Google Scholar
• Heimann H, Bornfeld N, Friedrichs W, et al. Primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment. Graefe’s Arch Clin Exp Ophthalmol 1996;234:561–568.
   PubMed Web of Science ®Google Scholar
• McCuen BW, Azen SP, Stern W, et al. Vitrectomy with silicone oil or perfluoropropane gas in eyes severe proliferative vitreoretinopathy. Silicone Study Report 3. Retina 1993;13:279–284.
   PubMed Web of Science ®Google Scholar
• Lewis H, Aaberg TM, Abrams GW. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 1991;111:8–19.
   PubMed Web of Science ®Google Scholar
• Elner SG, Elner VM, Jaffe GJ, et al. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045–1053.
   PubMed Web of Science ®Google Scholar
• Limb GA, Little BC, Meager A, et al. Cytokines in proliferative vitreoretinopathy. Eye 1991;5:686–693.
   PubMedGoogle Scholar
• Kosnosky W, Li TH, Pakalnis VA, et al. Interleukin 1-beta changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes containing preexisting retinal holes. Invest Ophthalmol Vis Sci 1994;35:4260–4267.
   PubMed Web of Science ®Google Scholar
• Kauffmann DJ, van Meurs JC, Mertens DA, et al. Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1994;35:900–906.
   PubMed Web of Science ®Google Scholar
• Camussi G, Albano E, Tetta C, et al. The moleculer action of tumor necrosis factor-alpha. Eur J Biochem 1991;202:3–14.
   PubMedGoogle Scholar
• Limb GA, Hollifield RD, Webster L, et al. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Opthalmol Vis Sci 2001;42:1586–1591.
   PubMed Web of Science ®Google Scholar
• Ferrick MR, Thurau SR, Oppenheim MH, et al. Ocular inflammation stimulated by intravitreal interleukin-8 and interleukin-1. Invest Ophthalmol Vis Sci 1991;32:1534–1539.
   PubMed Web of Science ®Google Scholar
• Kon CH, Occleston NL, Aylward GW, et al. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999;40:705–712.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Fredj-Reygrobellet D, Brignole F, et al. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res 1993;25:52–59.
   PubMed Web of Science ®Google Scholar
• Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and receptors immunolocalised in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994; 35:3649–3663.
   PubMed Web of Science ®Google Scholar
• Cassidy L, Barry P, Shaw C, et al. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. B J Ophthalmol 1998;82:181–185.
   PubMed Web of Science ®Google Scholar
• Connor TB, Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989;83:1661–1666.
   PubMed Web of Science ®Google Scholar
• Kita T, Hata Y, Kano K, et al. Transforming growth factor-β2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of rho kinase inhibitor. Diabetes 2007;56:231–238.
   PubMed Web of Science ®Google Scholar
• Bochaton-Piallat ML, Kapetanios AD, Donati G, et al. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 2000;41:2336–2342.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Kazlauskas A. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor. Invest Ophthalmol Vis Sci 2002;43:41–46.
   PubMed Web of Science ®Google Scholar
• Kita T, Hata Y, Arita R, et al. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 2008;105:17504–17509.
   PubMed Web of Science ®Google Scholar
• Evren O, Turgut B, Celiker U, et al. The impact of octreotide in experimental proliferative vitreoretinopathy. Indian J Ophthalmol 2013;61:109–114.
   PubMed Web of Science ®Google Scholar
• Dieudonne SC, La Heij EC, Diederen R, et al. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2004;45:4113–4118.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 2012;154:534–541.
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Mehryar M, et al. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010;30:1530–1535.
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 2012;28:628–631.
   PubMed Web of Science ®Google Scholar
• Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009;147:825–830.
   PubMed Web of Science ®Google Scholar
• Wu L, Hernandez-Bogantes E, Roca JA, et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011;31:298–303.
   PubMed Web of Science ®Google Scholar
• Arias L, Caminal JM, Badia MB, et al. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 2010;30:1601–1608.
   PubMed Web of Science ®Google Scholar
• Hamza MM, Macky TA, Sidky MK, et al. Intravitreal infliximab in refractory üveitis in Behcet’s disease: a safety and efficacy clinical study. Retina 2016;36:2399–2408.
   PubMed Web of Science ®Google Scholar
• Spraul CW, Kawen CK, Kampmeier JK, et al. Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro. Curr Eye Res 1999;19:483–490.
   PubMed Web of Science ®Google Scholar
• Baldysiak-Figiel A, Lang GK, Kampmeier J, et al. Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrinol 2004;180:417–424.
   PubMed Web of Science ®Google Scholar
• Luo Q, Peyman GA, Conway MD, et al. Effect of somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res 1996;15:909–913.
   PubMed Web of Science ®Google Scholar
• Spraul CW, Baldysiak-Figiel A, Lang GK, et al. Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefe’s Arch Clin Exp Ophthalmol 2002;240:227–231.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Borrelli F, Generini S, et al. Somatostatin-induced modulation of inflammation in experimental arthritis. Arthritis Rheum 1995;38:1687–1693.
   PubMed Web of Science ®Google Scholar
• Casnici C, Lattuada D, Crotta K, et al. Anti-inflammatory effect of somatostatin analogue octreotide on rheumatoid arthritis synoviocytes. Inflammation 2018;41:1648–1660.
   PubMed Web of Science ®Google Scholar